Risk factors
Madrigal Pharmaceuticals (MDGL) risk factors
Item 1A of every Madrigal Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors76 risks14 new11 dropped19 reworded
Rezdiffra commercialization now emphasizes reimbursement, EU pricing, specialty distributors, competition from over 140 MASH drugs, and post-approval regulatory compliance.
Filed Feb 19, 2026 - FY2024 10-K risk factors73 risks
Madrigal is a newly commercial-stage biopharmaceutical company focused entirely on the market acceptance and commercialization of Rezdiffra for MASH. The company relies on single-product viability, third-party manufacturers, specialty pharmacies, and external capital to fund operations.
Filed Feb 26, 2025